Rhythm Pharmaceuticals, Inc. RYTM Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $60.11M+83.8% | $57.25M+36.9% | $51.3M+54.3% | $48.5M+66.8% | $32.7M+25.9% | ||
| $7.16M+96.2% | $4.8M+26.8% | $5.5M+43.7% | $5.54M+88.1% | $3.65M+30.0% | ||
| $52.96M+82.3% | $52.45M+37.9% | $45.8M+55.7% | $42.96M+64.4% | $29.06M+25.5% | ||
| 88.1%-0.8pp | 91.6%+0.7pp | 89.3%+0.8pp | 88.6%-1.3pp | 88.8%-0.3pp | ||
| $41.73M+12.9% | $42.03M+2.1% | $46.03M+21.3% | $42.31M+40.1% | $36.97M-71.3% | ||
| $63.59M+62.7% | $57.48M+50.8% | $52.43M+48.2% | $45.95M+26.2% | $39.09M+13.7% | ||
| $112.47M+41.1% | $104.32M+25.6% | $103.95M+34.8% | $93.8M+34.9% | $79.71M-51.9% | ||
| -$52.36M-11.4% | -$47.06M-14.1% | -$52.65M-20.0% | -$45.3M-11.9% | -$47M+66.4% | ||
| -87.1%+56.6pp | -82.2%+16.4pp | -102.6%+29.3pp | -93.4%+45.8pp | -143.7%+395pp | ||
| $4.58M-15.3% | $4.62M-15.3% | $4.74M-9.5% | $5.82M+26.4% | $5.41M+13.8% | ||
| $3.55M-2.3% | $4.09M+16.2% | $4.33M+6.8% | $3.24M-20.9% | $3.64M+19.5% | ||
| -$2.73M-13.2% | -$473K— | -$140K-40.0% | -$999K-111% | -$2.41M-104% | ||
| -$55.09M-11.5% | -$47.54M-9.6% | -$52.79M-20.0% | -$46.3M-45.7% | -$49.42M+65.0% | ||
| $545K+581% | $0— | $111K+132% | $337K-29.6% | $80K-73.3% | ||
| -$55.64M-12.4% | -$47.51M-9.7% | -$52.9M-21.2% | -$46.63M-44.5% | -$49.5M+65.0% | ||
| -92.6%+58.8pp | -83%+20.5pp | -103.1%+28.1pp | -96.1%+14.8pp | -151.4%+393pp | ||
| -$0.83-2.5% | -$0.73-1.4% | -$0.82-12.3% | -$0.75-36.4% | -$0.81+65.5% | ||
| -$0.83-2.5% | -$0.73-1.4% | -$0.82-12.3% | -$0.75-36.4% | -$0.81+65.5% | ||
| 68M+7.8% | 65M+6.5% | 66.3M+8.2% | 63.7M+4.4% | 63.1M+4.8% | ||
| 68M+7.8% | 65M+6.5% | 66.3M+8.2% | 63.7M+4.4% | 63.1M+4.8% | ||
| -$54.4M-7.0% | -$48.71M-10.5% | -$52.96M-17.8% | -$50.18M-47.6% | -$50.83M+64.1% | ||
| $1.1M-16.5% | $1.33M-0.5% | $1.38M+3.5% | $1.35M+3.6% | $1.32M— | ||
| $3.55M-2.3% | $4.09M+16.2% | $4.33M+6.8% | $3.24M-20.9% | $3.64M+19.5% | ||
| -$544K-5,340% | $119K+129% | $488K-20.7% | -$93K+30.6% | -$10K+95.9% | ||
| $1.78M+89,300% | $0-100% | $834K+239% | -$2.1M-597% | -$2K+97.2% | ||
| -$1.7M-165% | $57K-82.5% | $274K-74.8% | $1.58M+422% | -$644K-223% | ||
| $60.11M+83.8% | $57.25M+36.9% | $51.3M+54.3% | $48.5M+66.8% | $32.7M+25.9% | ||
| -$52.36M-11.4% | -$47.06M-14.1% | -$52.65M-20.0% | -$45.3M-11.9% | -$47M+66.4% | ||
| —— | —— | —— | —— | —— | ||
| -$52.36M-11.4% | -$47.06M-14.1% | -$52.65M-20.0% | -$45.3M-11.9% | -$47M+66.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s revenue?
- Rhythm Pharmaceuticals, Inc. (RYTM) generated $217.2M in revenue over the trailing twelve months, up 58.7% year over year.
- Is Rhythm Pharmaceuticals, Inc. profitable?
- Rhythm Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $202.7M over the trailing twelve months, a -93.3% net margin.
- What are Rhythm Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 89.4% and operating margin is -90.9%, with a -93.3% net margin.
- What is Rhythm Pharmaceuticals, Inc.'s earnings per share?
- Rhythm Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-3.13.
- Where does Rhythm Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Rhythm Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
